U.S. Markets open in 5 hrs 49 mins
  • S&P Futures

    4,288.00
    -10.25 (-0.24%)
     
  • Dow Futures

    33,838.00
    -35.00 (-0.10%)
     
  • Nasdaq Futures

    13,640.50
    -40.75 (-0.30%)
     
  • Russell 2000 Futures

    2,020.20
    -3.60 (-0.18%)
     
  • Crude Oil

    89.13
    -0.28 (-0.31%)
     
  • Gold

    1,792.70
    -5.40 (-0.30%)
     
  • Silver

    20.10
    -0.17 (-0.85%)
     
  • EUR/USD

    1.0147
    -0.0018 (-0.1725%)
     
  • 10-Yr Bond

    2.7910
    0.0000 (0.00%)
     
  • Vix

    20.20
    +0.67 (+3.43%)
     
  • GBP/USD

    1.2030
    -0.0028 (-0.2334%)
     
  • USD/JPY

    133.7440
    +0.4720 (+0.3542%)
     
  • BTC-USD

    24,025.51
    -72.84 (-0.30%)
     
  • CMC Crypto 200

    569.88
    -20.89 (-3.54%)
     
  • FTSE 100

    7,538.36
    +29.21 (+0.39%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

Arcus Biosciences to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

HAYWARD, Calif., July 27, 2022--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a virtual fireside chat at the upcoming 13th Annual Wedbush PacGrow Healthcare Conference. The fireside chat will take place on Wednesday, August 10th, 2022 at 12:00 p.m. ET.

A live webcast of the fireside chat will be available by visiting the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and most recently, HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005061/en/

Contacts

Media Inquiries
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com

Investor Inquiries
Pia Banerjee
Head of Investor Relations & Strategy
(617) 459-2006
pbanerjee@arcusbio.com